Suppr超能文献

非转移性细胞1基因多态性与结直肠癌患者的临床进展及预后相关。

Nonmetastatic cell 1 gene polymorphisms are associated with the clinical progression and prognoses of patients with colorectal cancer.

作者信息

Liu Yabin, Bai Tianliang, Zhang Zhenxi, Xu Yanjun, Kong Dexian

机构信息

Department of General Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

Department of Gastrointestinal Surgery, Affiliated Hospital of Hebei University, Baoding, Hebei, China.

出版信息

Front Genet. 2025 May 9;16:1485855. doi: 10.3389/fgene.2025.1485855. eCollection 2025.

Abstract

BACKGROUND

Genetic polymorphisms in the nonmetastatic cell 1 gene () are reportedly associated with the risk of various tumors and the prognoses of cancer patients. The aims of this study were to evaluate the contribution of two polymorphisms of to the risk of colorectal cancer (CRC) development and the clinical outcomes of CRC patients in a northern Chinese population.

METHODS

This study included 453 CRC patients and 464 controls. Genotyping of two polymorphisms (rs2302254 and rs16949649) in the promoter region of was performed using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.

RESULTS

The results revealed that the rs2302254 and rs16949649 polymorphisms were not associated with the risk of CRC. However, the rs2302254 TT mutant genotype was associated with an increased risk for advanced clinical stage and lymph node metastasis. Moreover, survival analysis revealed that patients with the homozygous mutant TT genotype of rs2302254 had significantly shorter disease-free survival (DFS) and overall survival (OS) times than patients with the homozygous wild-type CC genotype.

CONCLUSION

The rs2302254 polymorphism might function as a potential molecular marker for predicting the progression and prognosis of CRC.

摘要

背景

据报道,非转移性细胞1基因()的基因多态性与各种肿瘤的风险及癌症患者的预后相关。本研究旨在评估该基因的两种多态性对中国北方人群结直肠癌(CRC)发生风险及CRC患者临床结局的影响。

方法

本研究纳入453例CRC患者和464例对照。采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法对该基因启动子区域的两种多态性(rs2302254和rs16949649)进行基因分型。

结果

结果显示,rs2302254和rs16949649多态性与CRC风险无关。然而,rs2302254的TT突变基因型与晚期临床分期及淋巴结转移风险增加相关。此外,生存分析显示,rs2302254纯合突变TT基因型患者的无病生存期(DFS)和总生存期(OS)明显短于纯合野生型CC基因型患者。

结论

rs2302254多态性可能作为预测CRC进展和预后的潜在分子标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c57f/12098514/255d16e60f02/fgene-16-1485855-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验